U.S. Software Stock News

NYSE:GOLF
NYSE:GOLFLeisure

Acushnet Holdings (GOLF) Is Down 7.5% After Profit Dip Despite Buybacks and New Product Sales - What's Changed

Acushnet Holdings Corp. reported first-quarter 2026 results, with sales rising to US$752.98 million while net income and earnings per share declined versus a year earlier. Over the same period, the company completed a multi-year buyback program totaling 19,275,829 shares for about US$1.02 billion, materially shrinking its share count. With revenue growth supported by new Titleist product launches but profits under pressure, we’ll examine how this shapes Acushnet’s investment narrative. The...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Gold.com (GOLD) Q3 Earnings Surge While Ultra Thin Margins Challenge Bullish Narratives

Gold.com (GOLD) just posted Q3 2026 results with revenue of about US$10.4b and net income of US$59.5m, equal to EPS of US$2.17, against a backdrop of 112.2% earnings growth over the past year and low net margins of around 0.3%. The company has seen quarterly revenue move from US$3.0b in Q3 2025 to US$10.4b in Q3 2026, while EPS shifted from a loss of US$0.36 to a profit of US$2.17 over the same periods, highlighting a combination of earnings momentum and thin margins for investors. See our...
NYSE:CWEN
NYSE:CWENRenewable Energy

Clearway Energy (CWEN) Valuation Check As Clean Power And Data Center Demand Narratives Gain Attention

What is moving Clearway Energy today With no single headline event driving trading, Clearway Energy (CWEN) is drawing attention as investors weigh its recent share performance and the company’s position in U.S. clean power generation and grid support. See our latest analysis for Clearway Energy. Recent trading has been softer, with a 7 day share price return of 5.5% and a 30 day share price return of 3.9%. However, a 12.3% year to date share price return and 40.1% 1 year total shareholder...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings

If you are wondering whether Viridian Therapeutics at around US$16.97 is priced for opportunity or risk, the key question is what that tag really says about the business. The stock has recently shown sharp moves, with returns of 25.9% over 7 days and 21.6% over 30 days, while year to date it is down 44.7% and up 32.8% over the past year. This mix of recent gains and earlier weakness has put valuation back in focus as investors reassess what they are willing to pay for Viridian Therapeutics...
NYSE:INSP
NYSE:INSPMedical Equipment

Inspire Medical Systems (INSP) Is Down 18.8% After Cutting 2026 Outlook And Filing Share Offering – Has The Bull Case Changed?

Inspire Medical Systems recently reported first-quarter 2026 results, with sales of US$204.58 million but a shift from net income to an US$11.29 million net loss, and subsequently filed a US$118.82 million shelf registration for 2,600,000 common shares tied to an ESOP-related offering. A key development for investors is the company’s revised 2026 outlook, which now calls for US$825 million to US$875 million in revenue, a 4% to 10% decline versus 2025, alongside expected diluted EPS of...
NYSE:LCII
NYSE:LCIIAuto Components

LCI Industries Faces Standalone Future After Patrick Merger Talks End

LCI Industries and Patrick Industries have ended merger of equals talks, halting plans to combine their RV supply operations. The termination marks a key corporate event that could affect how both businesses position themselves in the recreational vehicle supply sector. Investors now have to assess NYSE:LCII on a standalone basis, without potential merger related changes to scale or product breadth. LCI Industries, ticker NYSE:LCII, recently closed at $116.43, with the stock showing a 41.7%...
NasdaqGS:GSAT
NasdaqGS:GSATTelecom

Is It Too Late To Consider Globalstar (GSAT) After A 304% One Year Surge?

If you are wondering whether Globalstar's recent share price action still leaves any value on the table, it can help to start with a clear view of what the current valuation actually reflects so you can set expectations. The stock closed at US$81.48, with a 1% decline over the last 7 days, a 10.3% gain over 30 days, a 27.3% gain year to date, a 303.6% return over 1 year, a 432.5% return over 3 years, and a 412.5% return over 5 years. This performance already sets a high bar for what the...
NYSE:SKY
NYSE:SKYConsumer Durables

A Look At Champion Homes (SKY) Valuation After Sector-Wide Selloff On Rising Yields And Mortgage Rates

Champion Homes (SKY) stock dropped alongside other homebuilders after renewed Middle East tensions pushed Treasury yields and mortgage rates higher, pressuring affordability for new buyers and weighing on sector sentiment. See our latest analysis for Champion Homes. At a share price of $73.28, Champion Homes has seen a 3.5% one day share price decline and a 12.3% 90 day share price decline. The 5 year total shareholder return of 77.1% contrasts with a 1 year total shareholder return decline...
NYSE:BROS
NYSE:BROSHospitality

Dutch Bros (BROS) Margin Improvement Tests Expensive P/E After Strong Q1 2026 Results

Dutch Bros (BROS) opened Q1 2026 with revenue of US$464.4 million and basic EPS of US$0.13, alongside trailing 12 month revenue of US$1.7b and EPS of US$0.63 that frame the latest quarter within a larger earnings upswing in the data. Over recent periods, revenue has moved from US$355.2 million in Q1 2025 to US$464.4 million in Q1 2026, while quarterly EPS has ranged between US$0.13 and US$0.20, setting up a story where higher sales and advancing earnings feed into improving margins and a...
NasdaqGS:TEM
NasdaqGS:TEMLife Sciences

Is Tempus AI (TEM) Offering Value After Recent Share Price Volatility?

This article walks through key valuation numbers for Tempus AI so you can consider whether the current share price reflects its underlying value. The stock has had a mixed run lately, with a 10.9% drop over the last 7 days, a 5.6% gain over the last 30 days, and a 20.7% decline year to date, leaving the 1-year return at 24.2% in the red. Recent attention around Tempus AI has focused on its position within healthcare AI and how investors are weighing growth ambitions against execution risk...